

**Date:**18/10/2021

## **Stocks in News Today**

**HDFC Bank** | The company reported higher standalone profit at Rs 8,834 crore in Q2FY22 against Rs 7,513.11 crore in Q2FY21, net interest income rose to Rs 17,684.39 crore from Rs 15,776.39 crore YoY. News uploaded on Telegram: Neerajjoshi5014

**Avenue Supermarts** | The company reported sharply higher consolidated profit at Rs 418 crore for Q2FY22 against Rs 198.55 crore in Q2FY21, revenue surged to Rs 7,789 crore from Rs 5,306.20 crore YoY.

**HCL Technologies** | The company reported 1.6 percent sequential increase in consolidated profit at Rs 3,265 crore and 2.9 percent rise in revenue at Rs 20,655 crore in Q2FY22.

**United Drilling Tools** | Ashish Kacholia acquired 4 lakh equity shares in the company at Rs 357.5 per share, whereas Cairn Oil Solutions was the seller, offloading same number of shares at same price on the NSE, the bulk deals data showed.

**Just Dial** | Nalanda India Equity Fund sold 3.09 percent stake under open offer on October 13, reducing shareholding to 0.66 percent from 3.75 percent earlier.

**Fortis Healthcare** | Rakesh Jhunjhunwala's shareholding reduced in the company to 4.23 percent (3,19,50,000 shares) in September 2021 quarter, from 4.31 percent (3,25,50,000 shares) in June quarter.

**Indiabulls Real Estate** | The company reported consolidated profit at Rs 5.53 crore in Q2FY22 against loss of Rs 76.13 crore in Q2FY21, revenue rose to Rs 349.31 crore from Rs 20.15 crore YoY.

**Den Networks** | The company reported higher consolidated profit at Rs 39.39 crore in Q2FY22 against Rs 36.76 crore in Q2FY21, revenue fell to Rs 325 crore from Rs 337.6 crore YoY.

**Mahindra CIE Automotive** | The company reported higher consolidated profit at Rs 166.42 crore in Q2FY22 against Rs 60.76 crore in Q2FY21, revenue jumped to Rs 2,090.7 crore from Rs 1,694.3 crore YoY.

**Lupin** | Lupin Pharmaceuticals Inc is voluntarily recalling Irbesartan tablets (USP 75mg, 150mg and 300mg), and Irbesartan and Hydrochlorothiazide tablets (USP 150mg/12.5mg and 300mg/12.5mg) to the consumer level, in the US, although it has received no reports of illness that appear to relate to this issue.

**Cyient** | The company reported higher consolidated profit at Rs 121.3 crore in Q2FY22 against Rs 115 crore in Q1FY22, revenue jumped to Rs 1,111.6 crore from Rs 1,058.2 crore QoQ.